Article

On the Web: Neuropathy Resources

Conducting online research can be overwhelming. CURE makes it quick & easy by providing links to the best information from organizations we trust.

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of certain anti-cancer treatments. How these drugs affect the nerves differs depending on the amount of the drug used, the treatment schedule, the patient’s age and pre-existing issues that can put the patient at risk.

Conducting online research can be overwhelming. CURE makes it quick & easy by providing links to the best neuropathy information from organizations we trust.

CURE articles:

> "Lessons Learned: Peripheral Neuropathy from Cancer" at curetoday.com When trying to cope with peripheral neuropathy, sufferers could benefit from others’ success.

> "Numbing Down Neuropathy" at curetoday.com

Research and awareness help patients to understanding and manage chemotherapy-related peripheral neuropathy.

> "Tingling Troubles" at curetoday.com

Causes, prevention and management of peripheral neuropathy.

Other trusted resources:

> American Cancer Society on Neuropathy at cancer.org

> The Foundation for Peripheral Neuropathy> The Mayo Clinic at mayoclinic.org.

> The National Comprehensive Cancer Network’s “Management of Neuropathy in Cancer” at nccn.org

> The Neuropathy Support Network at neuropathysupportnetwork.org

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Image of doctor with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Related Content